Cogent Biosciences (COGT)
NASDAQ:COGT
Want to see COGT full AI Analyst Report?
COGT Stock Chart & Stats
$37.25
-$0.07(-0.91%)
At close: 4:00 PM EST
$37.25
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$4.20 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.36M
Market Cap
$5.90B
Enterprise Value$5.99B
Total Cash (Recent Filing)$900.76M
Total Debt (Recent Filing)$253.15M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 12, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding162,308,820
10 Day Avg. Volume1,794,347
30 Day Avg. Volume2,364,352
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.57K
Enterprise Value/Ebitda-17.96
Forecast
1Y Price Target
$52.55Price Target Upside41.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.12
Revenue Forecast (FY)$17.81M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyAnalyst cites pivotal Phase 3 SUMMIT results showing clinically meaningful and statistically significant improvements across primary and key secondary endpoints, indicating a clear therapeutic benefit in gastrointestinal stromal tumors.
Commercial Expansion PotentialAnalyst highlights Breakthrough Therapy Designation for the bezuclastinib plus sunitinib combination and multiple planned regulatory submissions, which could enable new approvals and broaden the drug's market opportunity.
Regulatory ProgressAnalyst notes FDA acceptance of the New Drug Application for bezuclastinib with no planned advisory committee and no identified review issues, supporting a potentially smooth review path toward approval.
Bears Say
Competitive PressureAnalyst cautions that entrenched competitors, including an established therapy marketed by a large pharmaceutical company, could constrain market share and require substantial commercial investment to displace incumbents.
Financial Dilution RiskAnalyst reiterates concern over high cash burn and a large fully diluted share count, indicating the potential need for additional financing that could dilute existing shareholders and pressure the stock.
Safety And Labeling RiskAnalyst warns that liver enzyme elevations and a higher incidence of thrombocytopenia at elevated doses could lead to restrictive labeling or a boxed warning, which would limit commercial uptake in some patient groups.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $4.20 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences’s market cap?
Cogent Biosciences’s market cap is $5.90B.
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is May 12, 2026 which is in 23 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Feb 17, 2026. The company reported -$0.61 earnings per share for the quarter, missing the consensus estimate of -$0.575 by -$0.035.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -0.53.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 162,308,820 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.61 in its last earnings report, missing expectations of -$0.575. Following the earnings report the stock price went up 2.984%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.55 (41.07% Upside)
$52.55 (41.07% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $370.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
747.54%
12-Months-Change
Fundamentals
Return on Equity
-100.22%
Trailing 12-Months
Asset Growth
185.94%
Trailing 12-Months
Company Description
Cogent Biosciences
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$52.55
▲(41.07% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
Currently, No data available
---